pegcetacoplan Syfovre
Selected indexed studies
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (N Engl J Med, 2021) [PMID:33730455]
- Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. (N Engl J Med, 2025) [PMID:41337715]
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. (Lancet, 2023) [PMID:37865470]
_Worker-drafted node — pending editorial review._
Connections
pegcetacoplan Syfovre is a side effect of
Sources
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (2021) pubmed
- Pegcetacoplan. (2012) pubmed
- Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. (2025) pubmed
- Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. (2023) pubmed
- Pegcetacoplan: First Approval. (2021) pubmed
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. (2023) pubmed
- Pegcetacoplan. (2023) pubmed
- Pegcetacoplan (Syfovre(ΤΜ)): targeting complement C3 in geographic atrophy. (2024) pubmed
- Pegcetacoplan (Syfovre) for geographic atrophy in age-related macular degeneration. (2023) pubmed
- Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. (2022) pubmed